Improved outcomes in patients with chronic obstructive pulmonary disease treated with salmeterol compared with placebo/usual therapy: results of a meta-analysis
<p>Abstract</p> <p>Background</p> <p>Several studies have demonstrated that long-acting β<sub>2</sub>-agonists such as salmeterol are beneficial in chronic obstructive pulmonary disease (COPD). A meta-analysis was therefore conducted to review studies in COP...
Main Authors: | Whitehead Philip J, Stockley Robert A, Williams Michael K |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2006-12-01
|
Series: | Respiratory Research |
Online Access: | http://respiratory-research.com/content/7/1/147 |
Similar Items
-
Retracted: Biochemical Behaviours of Salmeterol/Fluticasone Propionate in Treating Asthma and Chronic Obstructive Pulmonary Diseases (COPD)
by: Emergency Medicine International
Published: (2024-01-01) -
Antiinflammatory effects of salmeterol/fluticasone propionate in chronic obstructive lung disease.
by: Barnes, N, et al.
Published: (2006) -
Comparative Efficacy of Budesonide/Formoterol Versus Fluticasone/Salmeterol in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-Analysis
by: Nan Shang, et al.
Published: (2024-12-01) -
Can inhaled fluticasone alone or in combination with salmeterol reduce systemic inflammation in chronic obstructive pulmonary disease? – study protocol for a randomized controlled trial [NCT00120978]
by: Ramesh Warren, et al.
Published: (2006-02-01) -
Interaction and dose equivalence of salbutamol and salmeterol in patients with asthma.
by: Smyth, E, et al.
Published: (1993)